Chest Mobility, Strength, Physical Activity and Quality of Life in Parkinson's Patients With Post-COVID-19

Study Overview
=================
Brief Summary
-----------------
To comparative pain intensity, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with post-COVID-19 and without post-COVID-19 was aimed in current study. Knowledge in the literature regarding this topic is still obscure.

Detailed Description
-----------------
Acute worsening and long-term sequelae of motor and non-motor symptoms have also been described in Parkinson's patients during and after SARS-CoV-2 infection, which is also known as prolonged COVID. The effects of COVID-19 on pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients are still unclear today. For this reason, in this study, it was aimed to comparatively investigate pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with COVID-19 and without COVID-19 and to show the relationships between these outcome measures.

Official Title
-----------------
Chest Mobility, Cough Strength, Muscle Strength, Physical Activity and Quality of Life in Parkinson's Patients Who Have Had COVID-19

Conditions
-----------------
COVID-19 Respiratory Infection, Parkinson Disease

Intervention / Treatment
-----------------
* Other: Physical Evaluations of post-COVID-19 individuals
* Other: Physical Evaluations of non-post-COVID-19 individuals


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for Parkinson's patients with post-COVID-19; Being diagnosed with COVID-19 at least 12 weeks ago and recovered, Being over 18 years old, Volunteering to participate in the research, Being diagnosed with Parkinson's disease Comorbid conditions (such as hypertension, diabetes) are under control Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above) Having the ability to ambulate and walk independently Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale Inclusion criteria for Parkinson's patients without post-COVID-19; Not being diagnosed or suspected of COVID-19 Being over 18 years old, Volunteering to participate in the research, Being diagnosed with Parkinson's disease Having comorbid conditions (such as hypertension, diabetes) which are under control Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above) Having the ability to ambulate and walk independently Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale Exclusion criteria for Parkinson's patients with and without post-COVID-19; Sudden drug or dose change during the study period A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made. Having had myocardial infarction and pulmonary embolism in the last 30 days, Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease Having severe vision loss or vestibular dysfunction Patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on ECG, with a history of shortness of breath and/or palpitation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Post-COVID-19 group<br>This group will consist of individuals with Parkinson disease who have had COVID-19. | Other: Physical Evaluations of post-COVID-19 individuals<br>* In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.<br>|
| Control group<br>The control group will consist of individuals with Parkinson disease without post-COVID-19. | Other: Physical Evaluations of non-post-COVID-19 individuals<br>* In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total quality of life score evaluated by Parkinson's Disease Questionnaire (PDQ-39) questionnaire. | The status of quality of life will be evaluated using Parkinson's Disease Questionnaire (PDQ-39) questionnaire. Parkinson's Disease Questionnaire-39 (PDQ39) is a 39-item quality of life questionnaire. Evaluation for each question item ranges from 0 (no problem) to 4 (constant problem). Low scores in total indicate an improvement in people's quality of life. | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cough Strength | Cough Strength will be evaluated using a Peak Flow Meter. | through study completion, an average of 1 year | 
| Daily average step count | Daily average step counts will be recorded via a pedometer everyday within 3 days after confirming enrolment. All individuals will be asked to carry their pedometers with them during the day and record to their diaries. | through study completion, an average of 1 year | 
| Hand grip strength | Hand grip strength will be evaluated using a hand dynamometer. | through study completion, an average of 1 year | 
| Chest mobility | Chest mobility will be evaluated using a tape measure. | through study completion, an average of 1 year | 
| Cognitive status | Cognitive state will be evaluated using The mini-mental state examination (MMSE). It is an 11 question test. The highest score from the test is 30 points. Scores of 23 and lower indicate cognitive dysfunction, and scores of 24 and higher indicate normal cognitive level. | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, chest mobility, cough, muscle strength, physical activity, quality of life